Skip to main content
PMC home page
British Medical Journal logoLink to British Medical Journal
. 1969 Oct 18;4(5676):138–141. doi: 10.1136/bmj.4.5676.138

Adrenal function during topical oral corticosteroid treatment

Thomas Lehner, Cynthia Lyne
PMCID: PMC1629930  PMID: 4309863

Abstract

Plasma cortisol (hydrocortisone) levels were measured in 42 subjects before and during administration of topical oral corticosteroids. Topical administration of 0·3–0·4 mg. of betamethasone disodium phosphate daily caused partial suppression of adrenal function in 8 out of 10 subjects tested. The adrenal function remained normal in 14 patients treated with 10 mg. of hydrocortisone hemisuccinate daily for periods of up to three years. Betamethasone 17-valerate also failed to cause adrenal suppression in doses of 0·4 mg. per day in 17 patients. The adrenal glands failed to respond normally to stimulation with Synacthen (tetracosactrin) in selected subjects with depressed plasma cortisol levels. Therapeutic doses of topical oral hydrocortisone hemisuccinate and betamethasone 17-valerate may be used in adults with oral lesions without fear of affecting adrenal function. Betamethasone disodium phosphate, however, should be avoided, as it may cause adrenal suppression.

Full text

PDF
140

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. COOKE B. E., ARMITAGE P. Recurrent Mikulicz's aphthae treated with topical hydrocortisone hemisuccinate sodium. Double-blind controlled clinical trial. Br Med J. 1960 Mar 12;1(5175):764–766. doi: 10.1136/bmj.1.5175.764. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Czarny D., Brostoff J. Effect of intranasal betamethasone-17-valerate on perennial rhinitis and adrenal function. Lancet. 1968 Jul 27;2(7561):188–190. doi: 10.1016/s0140-6736(68)92621-4. [DOI] [PubMed] [Google Scholar]
  3. Dolton W. D. Social factors and the health of immigrants. Proc R Soc Med. 1968 Jan;61(1):19–21. [PMC free article] [PubMed] [Google Scholar]
  4. Friedman M., Fletcher J., Hinton J. M., Lennard-Jones J. E., Misiewicz J. J., Parrish J. A. Observations on the absorption of oral betamethasone 17-valerate and its therapeutic value in ulcerative colitis. Br Med J. 1967 Feb 11;1(5536):335–337. doi: 10.1136/bmj.1.5536.335. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Hicklin J. A., Wills M. R. Plasma "cortisol" response to Synacthen in patients on long-term small-dose prednisone therapy. Ann Rheum Dis. 1968 Jan;27(1):33–37. doi: 10.1136/ard.27.1.33. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Keczkes K., Frain-Bell W., Honeyman A. L., Sprunt G. The effect of adrenal function of treatment of eczema and psoriasis with triamcinolone acetonide. Br J Dermatol. 1967 Aug-Sep;79(8):475–486. doi: 10.1111/j.1365-2133.1967.tb11535.x. [DOI] [PubMed] [Google Scholar]
  7. LEHNER T. RECURRENT APHTHOUS ULCERATION AND AUTOIMMUNITY. Lancet. 1964 Nov 28;2(7370):1154–1155. doi: 10.1016/s0140-6736(64)92673-x. [DOI] [PubMed] [Google Scholar]
  8. Lehner T. Characterization of mucosal antibodies in recurrent aphthous ulceration and Behcet's syndrome. Arch Oral Biol. 1969 Jul;14(7):843–853. doi: 10.1016/0003-9969(69)90174-5. [DOI] [PubMed] [Google Scholar]
  9. Lessof M. H., Maisey M. N., Lyne C., Sturge R. A. Effect of thyroid failure on the pituitary-adrenal axis. Lancet. 1969 Mar 29;1(7596):642–644. doi: 10.1016/s0140-6736(69)92010-8. [DOI] [PubMed] [Google Scholar]
  10. MacPhee I. T., Sircus W., Farmer E. D., Harkness R. A., Cowley G. C. Use of steroids in treatment of aphthous ulceration. Br Med J. 1968 Apr 20;2(5598):147–149. doi: 10.1136/bmj.2.5598.147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. McHardy-Young S., Harris P. W., Lessof M. H., Lyne C. Singledose dexamethasone suppression test for Cushing's Syndrome. Br Med J. 1967 Jun 17;2(5554):740–744. doi: 10.1136/bmj.2.5554.740. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Raffle E. J., Frain-Bell W. The effect of topically applied beclamethasone dipropionate on adrenal function. Br J Dermatol. 1967 Aug-Sep;79(8):487–490. doi: 10.1111/j.1365-2133.1967.tb11536.x. [DOI] [PubMed] [Google Scholar]
  13. SCOGGINS R. B. Decrease of urinary corticosteroids following application of fluocinolone acetonide under an occlusive dressing. J Invest Dermatol. 1962 Dec;39:473–474. doi: 10.1038/jid.1962.145. [DOI] [PubMed] [Google Scholar]
  14. Scoggins R. B., Kliman B. Percutaneous absorption of corticosteroids: systemic effects. N Engl J Med. 1965 Oct 14;273(16):831–840. doi: 10.1056/NEJM196510142731601. [DOI] [PubMed] [Google Scholar]
  15. TRUELOVE S. C., MORRIS-OWEN R. M. Treatment of aphthous ulceration of the mouth. Br Med J. 1958 Mar 15;1(5071):603–607. doi: 10.1136/bmj.1.5071.603. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. WOOD J. B., FRANKLAND A. W., JAMES V. H., LANDON J. A RAPID TEST OF ADRENOCORTICAL FUNCTION. Lancet. 1965 Jan 30;1(7379):243–245. doi: 10.1016/s0140-6736(65)91526-6. [DOI] [PubMed] [Google Scholar]

Articles from British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES